3
12. 8. 2024.
Development of the 2023 ACR/EULAR Antiphospholipid Syndrome Classification Criteria, Phase III‐D Report: Multicriteria Decision Analysis
The 2023 American College of Rheumatology/EULAR antiphospholipid syndrome (APS) classification criteria development, which aimed to identify patients with high likelihood of APS for research, employed a four‐phase methodology. Phase I and II resulted in 27 proposed candidate criteria, which are organized into laboratory and clinical domains. Here, we summarize the last stage of phase III efforts, employing a consensus‐based multicriteria decision analysis (MCDA) to weigh candidate criteria and identify an APS classification threshold score.